Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Sodium Chloride 0.45% Solution for Infusion

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Sodium chloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Sodium chloride
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What you need to know before you take it

Sodium 0.45 Infusion

e

3.

How you will be given Sodium 0.45 Infusion

uncompensated heart failure. This is heart failure that is not adequately treated and causes symptoms such as:

4.

How to take it

Sodium 0.45

Please tell your doctor or nurse if you are taking, have recently taken or might take any other medicines.

TTC)

It is particularly important that you inform your doctor if

Sodium 0.45 Infusion will be given to you by a doctor or

you are taking:

nurse. Your doctor will decide on how much you need and when it is to be given. This will depend on your age, weight, condition, the reason for treatment and whether

e

corticosteroids (anti-inflammatory medicines)

e

-carbenoxolone (an anti-inflammatory medicine used to treat stomach ulcers) These medicines can cause the body to accumulate sodium and water, leading to:

or not the infusion is being used to deliver or dilute another medicine. The amount you are given may also be affected by other

treatments you are receiving. 2a

TH-30-02-266

You should NOT be given Sodium 0.45 Infusion if there are particles floating in the solution or if the pack is damaged in any way. Sodium 0.45 Infusion will usually be given to you through a plastic tube attached to a needle in a vein. Usually a vein in your arm is used to give you the infusion. However, your doctor may use another method to give you the medicine.

Before and during the infusion, your doctor will monitor: e

the amount of fluid in your body

e

the acidity of your blood and urine

e

the amount of electrolytes in your body (particularly sodium, in patients with high level of vasopressin, or are taking other medicines which increase the effect of vasopressin).

eg Se

ES

Like all medicines, this medicine can cause side effects, although not everybody gets them. e

too much fluid in the body (overhydration) which may lead to more frequent urination (polyuria)

e

changes in the concentrations of the chemicals in the blood (electrolyte disturbances)

e

heart failure, if you suffer from heart disease or fluid in the lungs (pulmonary oedema)

e

low levels of sodium in the blood that may be acquired during hospitalization (nosocomial hyponatraemia) and related neurological disorder (acute hyponatraemic encephalopathy). Hyponatraemia can lead to irreversible brain injury and death due to cerebral oedema/swelling (see also section 2 "Warnings and precautions").

This is especially important for children as they have a limited ability to regulate fluids and electrolytes. Any unused solution should be thrown away. You should NOT be given an infusion of Sodium 0.45 Infusion from a bag that has been partly used.

The side effects that may occur due to the administration technique include:

e

fever (febrile response)

If you receive more Sodium 0.45 Infusion than you should

e

infection at the site of infusion

If you are given too much Sodium 0.45 Infusion (overinfusion), or it is given too fast, this may lead to the following symptoms:

e e

build up of water in the body (oedema) too much water in the blood (haemodilution)

e

heart problems

e

e -_ local pain or reaction (redness or swelling at the site of infusion) e

irritation and inflammation of the vein into which the solution is infused (phlebitis). This can cause redness, pain or burning and swelling along the path of the vein into which the solution is infused

e

the formation of a blood clot (venous thrombosis) at the site of infusion, which causes pain, swelling or redness in the area of the clot

e

escape of the infusion solution into the tissues around the vein (extravasation). This can damage the tissues and cause scarring

acidification of the blood (acidosis), leading to tiredness, confusion, lethargy and increased breathing rate

If Sodium 0.45 Infusion is given too fast when you have higher than normal levels of salts in the blood (hypertonicity), swelling of the brain (brain oedema) is possible, especially if you often have higher than normal levels of sodium in the blood (hypernatraemia). If you develop any of these symptoms you must inform your doctor immediately. Your infusion will be stopped and you will be given treatment depending on the symptoms.

Other side effects noted with similar products (sodium

chloride containing solutions) include: e

acidification of the blood (hyperchloraemic metabolic acidosis)

e

reactions with the following symptoms have been reported:

  • – hives (urticaria) which may be localised to a part of the body or widespread

If a medicine has been added to your Sodium 0.45 Infusion before over-infusion occurs, that medicine may also cause symptoms. You should read the Package Leaflet of the added medicine for a list of possible symptoms.

If you stop receiving your Sodium 0.45 Infusion Your doctor will decide when to stop giving you this infusion.

If you have any further questions on the use of this

–

fever (pyrexia)

  • – skinrash –

Chills

  • – itching (pruritus) e

decreased blood pressure

Other infusion site reactions:

  • – hives at the infusion site.

If a medicine has been added to the solution for infusion, the added medicine may also cause side effects.

medicine, ask your doctor or nurse.

TH-30-02-266 3a

These side effects will depend on the medicine that has been added. You should read the Package Leaflet of the added medicine for a list of possible symptoms.

Reporting of side effects If you get any side effect, talk to your doctor or nurse.

This includes any possible side effect not listed in this leaflet. You can also report side effects directly via the national reporting system listed below. By reporting side effects, you can help provide more information on the safety of this medicine. United Kingdom: Via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard Ireland HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: [email protected].

The bags are supplied in cartons. Each carton contains 20 bags of 500 ml

Marketing Authorisation Holder and Manufacturers Marketing Authorisation Holder for the United Kingdom: Baxter Healthcare Ltd Caxton Way, Thetford, Norfolk, IP24 3SE

United Kingdom Manufacturers for Great Britain: Baxter SA Baxter Healthcare Ltd. Boulevard René Branquart, 80 Caxton Way, 7860 Lessines Thetford Norfolk IP24 3SE Belgium United Kingdom

Bieffe Medital Sabifanigo Ctra de Biescas, Senegiié 22666 Sabifanigo (Huesca) Spain

Malta

ADR Reporting Website: www.medicinesauthority.gov.mt/adrportal If any side effects occur, the infusion must be stopped.

Possible side effects

  • _

shortness of breath

How to store Sodium 0.45 Infusion

–

swelling of the ankles

5. 6.

How to store it

SODIUM 0.45 ye Keep this medicine out of the sight and reach of children. Sodium 0.45 Infusion does not require special storage conditions.

Sodium 0.45 Infusion should NOT be given to you after the expiry date which is stated on the bag after EXP. The expiry date refers to the last day of that month. You should not be given Sodium 0.45 Infusion, if there are particles floating in the solution or if the unit is damaged in any way.

6. Contents of the pack and other ee What Sodium 0.45 Infusion contains The active substance is sodium chloride: 4,5 g per litre. The only other ingredient is water for injections

What Sodium Chloride 0.45% Infusion looks like and contents of the pack Sodium Chloride 0.45% Solution for Infusion is a clear solution, free from visible particles. It is supplied in polyolefin/polyamide plastic bags (Viaflo). Each bag is wrapped in a sealed, protective, outer plastic overpouch. The bag size is 500 ml

Marketing Authorisation Holder for Ireland and Malta: Baxter Holding B.V. Kobaltweg 49, 3542CE Utrecht, Netherlands

Vantive Manufacturing Limited Moneen Road Castlebar County Mayo Ireland

Manufacturers for Ireland:

Baxter SA

Bieffe Medital Sabifanigo

Boulevard René Branquart, 80 7860 Lessines Belgium

Ctra de Biescas, Senegiié 22666 Sabinanigo (Huesca) Spain

Vantive Manufacturing Limited Moneen Road Castlebar County Mayo Ireland

This medicinal product is authorised in the Member States of the EEA under the following names: Ireland, UK: Sodium Chloride 0.45 % Solution for Infusion Finland: Natriumklorid Baxter Viaflo 4,5 mg/ml infuusioneste, liuos

This leaflet was last approved in May 2025 For information about Sodium Chloride 0.45% Infusion or to request this leaflet in formats such as audio or large print please contact the Marketing Authorisation Holder:

Tel: +44 (0)1635 206345.

Baxter and Viaflo are trademarks of Baxter International Inc.

Mano TH-30-02-266

4a

Sodium Chioride 0.45 % Solution for Infusion The following information is intended for medical or healthcare professionals only: Handling and Preparation

2.

Preparation for administration

Use sterile material for preparation and administration. a. Suspend container from eyelet support. b. Remove plastic protector from outlet port at bottom of container: –

Use only if the solution is clear, without visible particles

and if the container is undamaged. Administer immediately following the insertion of infusion set. Do not remove unit from overwrap until ready for use.

The inner bag maintains the sterility of the product. Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is completed. Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration. The solution should be administered with sterile equipment using an aseptic technique. The equipment should be primed with the solution in order to prevent air

entering the system. Additives may be introduced before infusion or during infusion through the re-sealable medication port. When additive is used, verify isotonicity prior to parenteral administration. Thorough and careful aseptic mixing of any additive is mandatory. Solutions containing additives should be used immediately and not stored. Adding medication or using an incorrect administration technique might cause the appearance of fever reactions due to the possible introduction of pyrogens. In case of adverse reaction, infusion must be stopped immediately.

c d.

grip the small wing on the neck of the port with one hand, grip the large wing on the cap with the other hand and twist, the cap will pop off. Use an aseptic method to set up the infusion. Attach administration set. Refer to complete directions accompanying set for connection,

priming of the set and administration of the solution.

3. Techniques for injection of additive medications Warning: Additives may be incompatible (see paragraph 5 "Incompatibilities of additive medications" below). To add medication before administration a. b.

Disinfect medication port. Using syringe with 19 (1.10 mm) to 22 (0.70 mm) gauge needle, puncture re-sealable medication port and inject.

c.

Mix solution and medication thoroughly. For high-density medication such as potassium chloride, tap the ports gently while ports are upright and mix.

Caution: Do not store bags containing added medications.

To add medication during administration Do not mix or administer Sodium 0.45 Infusion through the same administration set with whole blood or cellular blood components.

a. b. c.

Discard after single use. Discard any unused portion.

d.

Do not reconnect partially used bags.

1. Opening a. b.

c.

Remove the Viaflo container from the overpouch just before use. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution, as sterility may be impaired. Check the solution for limpidity and absence of foreign matters. If solution is not clear or contains foreign matters, discard the solution.

4.

Close clamp on the set Disinfect medication port. Using syringe with 19 (1.10 mm) to 22 (0.70 mm) gauge needle, puncture re-sealable medication port and inject. Remove container from IV pole and/or turn to an upright position.

e.

Evacuate both ports by tapping gently while the container is in an upright position.

f. g.

Mix solution and medication thoroughly. Return container to in use position, re-open the clamp and continue administration

In-use shelf life (Additives)

Chemical and physical stability of any additive medication at the pH of the Sodium 0.45 Infusion in the Viaflo container should be established prior to use.

TH-30-02-266 1b

From a microbiological point of view, the diluted product must be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C unless dilution has taken place in controlled and validated aseptic conditions.

5.

Incompatibilities of additive medications

As with all parenteral solutions, incompatibility of the additive medications with the solution in Viaflo container must be assessed before addition. Those additives known to be incompatible should not be used. In the absence of compatibility studies, this solution must not be mixed with other medicinal products. It is the responsibility of the healthcare professional to judge the incompatibility of an additive medication with the Sodium 0.45 Infusion, by checking for eventual colour change and/or eventual appearance of precipitate, insoluble complexes or crystals. The Instructions for Use of the medication to be added must be consulted. Before adding a drug, verify it is soluble and/or stable in water at the pH of the Sodium 0.45 Infusion (pH 4.5 to

7.0).

Baxter and Viaflo are trademarks of Baxter International Inc.

Mano TH-30-02-266

2b

Contents of the pack and other information

blood (fluid or sodium retention)

e -_ build up of fluid under the skin, affecting all parts of the body (general oedema) e

TEST RU OR TS Nem erste reg

erelite

Sodium 0.45 Infusion is a solution of sodium chloride in water. Sodium chloride is a chemical substance (often called "salt") found in the blood. Sodium 0.45 Infusion is used to treat: e

e

aloss of body water, for example after being sick or having diarrhoea (hypertonic extracellular dehydration) alower than normal volume of blood in the body

(hypovolaemia)

liver disease that causes fluid to build up within the abdomen (ascitic cirrhosis)

If a medicine has been added to Sodium 0.45 Infusion,

the Package Leaflet of the added medicine must be consulted to determine whether or not you can receive the solution.

Warnings and precautions Please tell your doctor if you have or have had any of the following medical conditions:

e e e

any type of heart disease or poor heart function poor kidney function respiratory failure (lung disease) (special monitoring may be required in the above

Sodium 0.45 infusion may also be used to deliver or to dilute other medicines for infusion.

conditions) e

raised production of the hormone aldosterone (aldosteronism)

e

when there is a larger volume of blood in the blood vessels than there should be (hypervolaemia)

e

high blood pressure (hypertension)

e

high blood pressure during pregnancy (preeclampsia)

TH-30-02-266 la

e

  • _ tissue swelling due to fluid collection under the

any other condition associated with sodium and fluid

retention (when the body retains too much sodium

skin (oedema)

or water), such as treatment with steroids (See also

below "Taking other medicines") e

if you have a condition that could cause high levels

–

Lithium (used to treat psychiatric illness)

¢

Some medicines act on the hormone vasopressin. These may include:

of vasopressin, a hormone regulating fluid in your

  • – anti-diabetic medication (chlorpropamide)

body. You may have too much vasopressin in your body because, for example: –

you have had a sudden and serious illness

–

you are in pain

–

you have had surgery

–

you have infections, burns or brain disease

–

you have diseases linked to your heart, liver, kidneys or central nervous system

–

  • – cholesterol medicine (clofibrate)

women (particularly if you are of a fertile age)

–

people who have problems with their brain fluid levels, for example, because of meningitis, bleeding in the skull or a brain injury.

Some patients are at higher risk for having or developing a too low sodium concentration in your blood (hyponatraemia). In general this applies to: ®

young and old people

*

women

©

anyone with a condition such as low levels of oxygen

in your blood (hypoxemia) e – drinking a lot due to a dry mouth (psychogenic polydipsia)

–

selective serotonin reuptake inhibitors (used to treat depression)

–

antipsychotics

–

opioids for severe pain relief

–

medicines for pain and/or inflammation (also medicines that imitate or strengthen the effects

of vasopressin such as desmopressin (used to

This may increase the risk of low levels of sodium in your blood and can lead to headache, nausea, seizures, lethargy, coma, swelling of the brain and death. Brain swelling increases the risk of death and brain damage. People who are at higher risk of brain swelling are: –

some cancer drugs (vincristine, ifosfamide, cyclophosphamide)

known as NSAIDs)

Infusion").

children

–

–

because you are taking certain medicines (see also below "Other medicines and Sodium 0.45

–

high blood pressure (hypertension)

e

treat increased thirst and urination), terlipressin

(used to treat bleeding of the gullet) and oxytocin (used to induce labour)

oxcarbazepine) –

diuretics (water tablets).

Sodium 0.45 Infusion with food and drink You should ask your doctor about what you can eat or drink.

Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or nurse for advice before taking this medicine. If another medicine is to be added to your solution for

infusion during pregnancy or breast-feeding you should: ®

consult your doctor

e

read the Package Leaflet of the medicine that is to be added

e

if you have recently been operated on

e

if you have certain diseases of the nervous system

Driving and using machines

e

if you are taking certain antiepileptic and psychiatric medicines

Ask your doctor or nurse for advice before driving or using machines.

Other medicines and Sodium 0.45 Infusion

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine.
Medicines with the same active substance: Sodium chloride (98 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Sodium Chloride 0.45% Solution for Infusion is indicated for the treatment of hypertonic extracellular dehydration or hypovolaemia in cases where the intake of fluids and electrolytes by normal routes is not possible.

It can also be used as a vehicle or diluent of compatible medicinal products.

4.2. Posology and method of administration

Posology

Adults, older people, Adolescents and Children:

Fluid balance, serum electrolytes and acid-base balance should be monitored before and during administration, with particular attention to serum sodium in patients with increased non-osmotic vasopressin release (syndrome of inappropriate antidiuretic hormone secretion, SIADH) and in patients co-medicated with vasopressin agonist drugs, due to the risk of hospital acquired hyponatraemia (see sections 4.4, 4.5 and 4.8). Monitoring of serum sodium is particularly important for hypotonic fluids.

Sodium Chloride 0.45% Solution for Infusion has a tonicity of 154 mOsm/l (approx.)

The infusion rate and volumedepend on age, weight, clinical condition (e.g. burns, surgery, head-injury, infections),and concomitant therapy should be determined by the consulting physician experienced in intravenous fluid therapy (see sections 4.4. and 4.8).

Recommended dosage:

- For adults, older people and adolescents: 500 ml to 3 litres/24h,

- For babies and children: 20 to 100 ml per 24 h and per kg of body weight, depending on the age and the total body mass.

The recommended dosage when used as a vehicle or diluent ranges from 50 to 250 ml per dose of medicinal product to be administered.

Administration rate:

The infusion rate depends on the patient clinical conditions. It is usually:

40 ml/kg/24h for adults, older people and adolescents,

- 5 ml/kg/h in average for paediatric patients but the value varies with age:

- 6-8 ml/kg/h for infants,

- 4-6 ml/kg/h for toddlers,

- 2-4 ml/kg/h for schoolchildren.

f

Note:

- Infants and toddlers: age ranges from about 28 days to 23 months (a toddler is an infant who can walk),

- Children and schoolchildren: age ranges from about 2 years to 11 years.

When Sodium Chloride 0.45% Solution for Infusion is used as a diluent for injectable preparations of other medicinal products, the infusion rate will also be dictated by the nature and the dose regimen of the prescribed medicinal products.

Method of Administration:

The solution is for administration by intravenous infusion through a sterile and non-pyrogenic administration set, using aseptic technique. The equipment should be primed with the solution to prevent air entering the system.

The product should be inspected visually for particulate matter and discoloration prior to administration. Do not administer unless solution is clear, free from visible particles and the seal is intact.

Do not remove unit from overwrap until ready for use. The inner bag maintains the sterility of the solution. Administer immediately following the insertion of infusion set.

Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container. Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration. Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.

Additives may be introduced before infusion or during infusion through the injection site. Adding other medication or using an incorrect administration technique might cause the appearance of fever reactions due to the possible introduction of pyrogens. If an adverse event occurs the patient evaluated and appropriate countermeasures started. If needed the infusion should be stopped.

For information on incompatibilities and preparation of the product with additives, please see sections 6.2 and 6.6.

4.3. Contraindications

The solution is contra-indicated in patient presenting:

- Hyponatraemia, hypochloraemia,

- Extracellular hyperhydration or hypervolaemia,

Severe renal insufficiency (with oliguria/anuria),

Fluid and sodium retention,

Uncompensated cardiac failure,

General oedema and ascitic cirrhosis.

The contra-indications related to the added medicinal product should be considered.

4.4. Special warnings and precautions for use

Electrolyte balance

Hyponatraemia/Hypernatraemia

The infusion of solutions with sodium concentrations <0.9% may result in hyponatraemia.

High volume infusion must be used under specific monitoring in patients with cardiac or pulmonary failure and in patients with non-osmotic vasopressin release (including SIADH), due to the risk of hospital-acquired hyponatraemia (see below).

Hyponatraemia

Patients with non-osmotic vasopressin release (e.g. in acute illness, pain, post-operative stress, infections, burns, and CNS diseases), patients with heart-, liver- and kidney diseases and patients exposed to vasopressin agonists (see section 4.5) are at particular risk of acute hyponatraemia upon infusion of hypotonic fluids.

Acute hyponatraemia can lead to acute hyponatraemic encephalopathy (cerebral oedema) characterized by headache, nausea, seizures, lethargy, and vomiting. The risk for hyponatraemia is increased, for example,

• in children

• in elderly patients

• in women

• in patients with hypoxemia

• in patients with underlying central nervous system disease

• postoperatively

• in persons with psychogenic polydipsia

in patients treated with medications that increase the risk of hyponatraemia (such as certain antiepileptic and psychotropic medications).

Patients with cerebral oedema are at particular risk of severe, irreversible and life-threatening brain injury. Children, women in the fertile age and patients with reduced cerebral compliance (e.g. meningitis, intracranial bleeding, cerebral contusion and brain oedema) are at particular risk of the severe and life-threatening brain swelling caused by acute hyponatraemia.

Acute symptomatic hyponatraemic encephalopathy is considered a medical emergency.

Hyponatraemia should be corrected at a calculated rate to prevent hyponatraemic encephalopathy.

Rapid correction of hyponatraemia and hypernatremia is potentially dangerous (risk of serious neurologic complications). Rapidly correcting hypernatremia once adaptation has occurred may lead to cerebral oedema, potentially resulting in seizures, permanent brain damage, or death.

Dosage, rate, and duration of administration should be determined by a physician experienced in intravenous fluid therapy.

Fluid balance/renal function

Use in patients with moderate renal impairment

The product should be administered with particular caution to patients with moderate renal impairment. In such patients administration of Sodium Chloride 0.45% Solution for Infusion may result in sodium retention.

Risk of fluid and/or solute overload and electrolyte disturbances

Depending on the volume and rate of infusion, intravenous administration of Sodium Chloride 0.45% Solution for Infusion can cause

• Fluid and/or solute overload resulting in over hydration/hypervolemia and, for example, congested states, including central and peripheral oedema.

• Clinically relevant electrolyte disturbances and acid-base imbalance.

In general; the risk of dilutional states is inversely proportional to the electrolyte concentrations in the solution and additions. The risk of solute overload causing congested states is directly proportional to the electrolyte concentration in the solution and its additions.

Clinical evaluation and periodic laboratory determinations may be necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation.

Use in patients at risk for sodium retention, fluid overload and oedema

Sodium Chloride 0.45% Solution for Infusion should be used with particular caution, if at all, in patients with or at risk for:

• Hypervolemia

• Conditions that may cause sodium retention, fluid overload and oedema (central and peripheral), such as patients with

- primary hyperaldosteronism,

- secondary hyperaldosteronism associated with, for example,

- hypertension,

- congestive heart failure,

- liver disease (including cirrhosis),

- renal disease (including renal artery stenosis, nephrosclerosis) or

- pre-eclampsia.

Medications that may increase the risk of sodium and fluid retention, such as corticosteroids.

Infusion reactions

Symptoms of unknown aetiology which can appear to be hypersensitivity reactions have been reported very rarely in association with parenteral infusion of Sodium Chloride. These have been characterized as hypotension, pyrexia, tremor, chills, urticaria, rash and pruritus. Stop the infusion immediately if signs or symptoms of these reactions develop. Appropriate therapeutic countermeasures should be instituted as clinically indicated.

Specific patient groups

The consulting physician should be experienced in this product's use and safety in these special populations that are especially sensitive to rapid changes in serum sodium levels.

Rapid correction of hyponatraemia and hypernatremia is potentially dangerous (risk of serious neurologic complications). see section “Hyponatraemia/hypernatraemia” above.

Paediatric population

Plasma electrolyte concentrations should be closely monitored in the paediatric population as this population may have impaired ability to regulate fluids and electrolytes. Repeated infusions of sodium chloride should only be given after determination of serum sodium level.

The infusion of hypotonic fluids together with the non-osmotic secretion of ADH may result in hyponatraemia. Hyponatraemia can lead to headache, nausea, seizures, lethargy, coma, cerebral oedema and death, therefore acute symptomatic hyponatraemic encephalopathy is considered a medical emergency.

Geriatric population

In older people, the risk for hyponatraemia is increased. When selecting the type of infusion solution and the volume/rate of infusion for a geriatric patient, consider that geriatric patients are generally more likely to have cardiac, renal, hepatic, and other diseases or concomitant drug therapy.

Other warnings

Osmolarity

Sodium Chloride 0.45% Solution for Infusion is hypotonic with an osmolarity of approximately 154 mOsmol/L.

Administration with blood products

Do not mix or administer Sodium Chloride 0.45% Solution for Infusion through the same administration set with whole blood or cellular blood components.

During long-term infusion, the doctor can decide to give you an appropriate nutritive supply.

As with all parenteral solutions, compatibilities should be checked when additives are used (see section 6.2).

4.5. Interaction with other medicinal products and other forms of interaction

Interaction related to the presence of sodium:

Corticoids/Steroids and carbenoxolone, which are associated with the retention of sodium and water (with oedema and hypertension), see section 4.4 special warnings and precautions for use.

Drugs leading to an increased vasopressin effect:

The below listed drugs increase the vasopressin effect, leading to reduced renal electrolyte free water excretion and may increase the risk of hospital acquired hyponatraemia following inappropriately balanced treatment with i.v. fluids (see sections 4.2, 4.4 and 4.8).

• Drugs stimulating vasopressin release include: Chlorpropamide, clofibrate, carbamazepine, vincristine, selective serotonin reuptake inhibitors, 3.4-methylenedioxy-N-methamphetamine, ifosfamide, antipsychotics, narcotics

• Drugs potentiating vasopressin action include: Chlorpropamide, NSAIDs, cyclophosphamide

• Vasopressin analogues include: Desmopressin, oxytocin, terlipressin

Other medicinal products increasing the risk of hyponatraemia also include diuretics in general and antiepileptics such as oxcarbazepine.

Caution is advised in patients treated with lithium. Renal sodium and lithium clearance may be decreased in the presence of hyponatraemia. Administration of Sodium Chloride 0.45% Solution for Infusion may result in increased lithium levels.

4.6. Pregnancy and lactation

There are no adequate data from the use Sodium Chloride 0.45% Solution for Infusion in pregnant or lactating women. The physician should carefully consider the potential risks and benefits for each specific patient before administering Sodium Chloride 0.45% Solution.

Sodium Chloride 0.45% Solution for Infusion should be administrated with special caution for pregnant women during labour particularly as to serum-sodium if administered in combination with oxytocin (see section 4.4, 4.5 and 4.8).

When a medicinal product is added, the nature of the drug and its use during pregnancy and lactation have to be considered separately.

4.7. Effects on ability to drive and use machines

There is no information on the effects of Sodium Chloride 0.45% Solution for Infusion on the ability to operate an automobile or other heavy machinery

4.8. Undesirable effects

the following undesirable effects have been reported to have occurred during or following infusion of Sodium Chloride 0.45% Solution for Infusion.

System Organ Class

Symptoms (LLT terms MedDRA)

Metabolism and nutrition disorders

Overhydration* (associated or not with polyuria) in patients with cardiac disorder or pulmonary oedema

Asymptomatic electrolyte disturbance

Hyponatraemia

Hospital acquired hyponatraemia**

Nervous system disorders

Acute hyponatraemic encephalopathy**

Cardiac disorders

Heart failure in patients with cardiac disorder or pulmonary oedema

Vascular disorders

Thrombophlebitis*

Venous thrombosis*

General disorders and administration site conditions

Fever*

Injection site pain*

Injection site reaction*

Injection site phlebitis*

Injection site irritation*

Injection site infection*

Extravasation*

The frequency of the adverse drug reactions listed in this section cannot be estimated from the available data

* Adverse reactions associated with the technique of administration

**Hospital acquired hyponatraemia may cause irreversible brain injury and death, due to development of acute hyponatraemic encephalopathy, frequency unknown (see sections 4.2. 4.4, 4.5).

The following adverse reactions have not been reported with this product but may occur:

• Hyperchloraemic metabolic acidosis

• Infusion reactions, including hypotension, tremor, chills, urticaria, rash, and pruritus.

Adverse reactions may be associated to the medicinal products added to the solution; the nature of the additive will determine the likelihood of any other undesirable effects.

If an adverse event occurs the patient should be evaluated and appropriate countermeasures started, if needed the infusion should be stopped

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme.

Website: www.mhra.gov.uk/yellowcard

4.9. Overdose

An excessive volume of Sodium Chloride 0.45% Solution for Infusion may lead to:

• hypo- and hypernatremia (which can lead to CNS manifestations, including seizures, coma, cerebral oedema and death) and

• sodium overload (which can lead to central and/or peripheral oedema).

See also section 4.4.

Excessive administration of chloride salts may cause a loss of bicarbonate with an acidifying effect.

When Sodium Chloride 0.45% Solution for Infusion is used as a diluent for injectable preparations of other medicinal products, the signs and symptoms of over infusion will be related to the nature of the additives being used.

In the event of accidental over infusion, treatment should be discontinued and the patient should be observed for the appropriate signs and symptoms related to the drug administered. The relevant and supportive measures should be provided as necessary.

💬 Ask about this leaflet

Ask anything about Sodium Chloride 0.45% Solution for Infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →